Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients

Transplant Cell Ther. 2024 Mar;30(3):306.e1-306.e12. doi: 10.1016/j.jtct.2023.12.672. Epub 2024 Jan 5.

Abstract

Chimeric antigen receptor T cells (CAR-T) has emerged as a promising therapy, over 60% of patients fail to sustain a long-term response. The underlying factors that leads to the effectiveness of this therapy are not completely understood, CAR-T cell persistence and monitoring seems to be pivotal for ensuring a successful response. Various monitoring methods such as multiparametric flow cytometry (MFC) or quantitative PCR (qPCR) have been applied. Our objective is to develop digital PCR (dPCR) assays for detection and quantification of CAR-T cells, comparing them with MFC and qPCR. Samples taken at different follow-up times from 45 patients treated with CAR-T therapy were analyzed to assess the correlation between the different methodologies. dPCR presented a high correlation with MFC and qPCR (r = 0.97 and r = 0.87, respectively), while offering a higher sensitivity (0.01%) compared to MFC (0.1%) and qPCR (1%). dPCR emerged as an alternative and highly sensitivity method for monitoring CAR-T cell dynamics. This technique is well-suited for implementation in clinical practice as a complementary technique to MFC.

Keywords: CAR-T cells; Digital PCR; Monitoring; Relapse; Sensitivity; Toxicity.

MeSH terms

  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Lymphoma, B-Cell* / etiology
  • Polymerase Chain Reaction
  • Receptors, Chimeric Antigen* / genetics
  • T-Lymphocytes

Substances

  • Receptors, Chimeric Antigen